Dishman Carbogen Amcis Limited (DCAL.NS)
INR 209.88
(2.91%)
INR 209.88
(2.91%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 5.14 Billion INR | -72.18% |
| 2022 | 18.5 Billion INR | 11.99% |
| 2021 | 16.51 Billion INR | 14.7% |
| 2020 | 14.4 Billion INR | 7.9% |
| 2019 | 13.34 Billion INR | 2.41% |
| 2018 | 13.03 Billion INR | 19.43% |
| 2017 | 10.91 Billion INR | -3.29% |
| 2016 | 11.28 Billion INR | 19.08% |
| 2015 | 9.47 Billion INR | 10.05% |
| 2014 | 8.61 Billion INR | 9.38% |
| 2013 | 7.87 Billion INR | 15.47% |
| 2012 | 6.81 Billion INR | 17.16% |
| 2011 | 5.81 Billion INR | 42.74% |
| 2010 | 4.07 Billion INR | -1.66% |
| 2009 | 4.14 Billion INR | -10.14% |
| 2008 | 4.61 Billion INR | 33.04% |
| 2007 | 3.46 Billion INR | 46.82% |
| 2006 | 2.36 Billion INR | 225.1% |
| 2005 | 726.57 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.16 Billion INR | 30.9% |
| 2023 Q2 | 4.66 Billion INR | -8.3% |
| 2023 Q1 | 5.08 Billion INR | 9.75% |
| 2023 FY | 5.14 Billion INR | -72.18% |
| 2023 Q4 | 891.2 Million INR | -14.99% |
| 2023 Q3 | 1.04 Billion INR | -77.53% |
| 2022 FY | 18.5 Billion INR | 11.99% |
| 2022 Q1 | 4.35 Billion INR | -6.49% |
| 2022 Q2 | 4.53 Billion INR | 4.21% |
| 2022 Q4 | 4.63 Billion INR | -6.83% |
| 2022 Q3 | 4.97 Billion INR | 9.64% |
| 2021 Q4 | 4.65 Billion INR | 16.78% |
| 2021 FY | 16.51 Billion INR | 14.7% |
| 2021 Q2 | 3.91 Billion INR | -1.26% |
| 2021 Q1 | 3.96 Billion INR | 24.62% |
| 2021 Q3 | 3.98 Billion INR | 1.89% |
| 2020 FY | 14.4 Billion INR | 7.9% |
| 2020 Q4 | 3.18 Billion INR | -19.4% |
| 2020 Q3 | 3.94 Billion INR | 6.39% |
| 2020 Q2 | 3.7 Billion INR | 8.41% |
| 2020 Q1 | 3.42 Billion INR | -7.08% |
| 2019 Q1 | 3.18 Billion INR | -30.59% |
| 2019 FY | 13.34 Billion INR | 2.41% |
| 2019 Q2 | 3.11 Billion INR | -2.36% |
| 2019 Q4 | 3.68 Billion INR | 9.43% |
| 2019 Q3 | 3.36 Billion INR | 8.07% |
| 2018 Q3 | 2.8 Billion INR | -4.06% |
| 2018 Q2 | 2.92 Billion INR | 7.49% |
| 2018 Q1 | 2.71 Billion INR | -1.24% |
| 2018 Q4 | 4.59 Billion INR | 63.86% |
| 2018 FY | 13.03 Billion INR | 19.43% |
| 2017 Q4 | 2.75 Billion INR | 5.36% |
| 2017 FY | 10.91 Billion INR | -3.29% |
| 2017 Q3 | 2.61 Billion INR | -4.28% |
| 2017 Q2 | 2.72 Billion INR | 0.18% |
| 2017 Q1 | 2.72 Billion INR | -2.71% |
| 2016 Q1 | 2.38 Billion INR | -2.33% |
| 2016 Q2 | 2.5 Billion INR | 5.13% |
| 2016 Q4 | 2.8 Billion INR | 26.34% |
| 2016 Q3 | 2.21 Billion INR | -11.43% |
| 2016 FY | 11.28 Billion INR | 19.08% |
| 2015 Q3 | 2.15 Billion INR | -1.32% |
| 2015 Q4 | 2.43 Billion INR | 13.26% |
| 2015 FY | 9.47 Billion INR | 10.05% |
| 2015 Q1 | 2.39 Billion INR | 3.9% |
| 2015 Q2 | 2.18 Billion INR | -8.84% |
| 2014 Q4 | 2.3 Billion INR | 9.64% |
| 2014 Q3 | 2.09 Billion INR | 0.1% |
| 2014 Q1 | 2.12 Billion INR | -9.25% |
| 2014 Q2 | 2.09 Billion INR | -1.18% |
| 2014 FY | 8.61 Billion INR | 9.38% |
| 2013 Q4 | 2.33 Billion INR | 24.9% |
| 2013 Q3 | 1.87 Billion INR | -4.29% |
| 2013 Q2 | 1.95 Billion INR | 14.79% |
| 2013 Q1 | 1.7 Billion INR | -12.03% |
| 2013 FY | 7.87 Billion INR | 15.47% |
| 2012 Q3 | 1.65 Billion INR | 5.36% |
| 2012 Q4 | 1.93 Billion INR | 17.22% |
| 2012 Q1 | 1.65 Billion INR | 5.57% |
| 2012 FY | 6.81 Billion INR | 17.16% |
| 2012 Q2 | 1.56 Billion INR | -5.37% |
| 2011 Q4 | 1.57 Billion INR | 6.68% |
| 2011 Q3 | 1.47 Billion INR | 0.0% |
| 2011 FY | 5.81 Billion INR | 42.74% |
| 2010 FY | 4.07 Billion INR | -1.66% |
| 2009 FY | 4.14 Billion INR | -10.14% |
| 2008 FY | 4.61 Billion INR | 33.04% |
| 2007 FY | 3.46 Billion INR | 46.82% |
| 2006 FY | 2.36 Billion INR | 225.1% |
| 2005 FY | 726.57 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Biocon Limited | 40.9 Billion INR | 87.416% |
| Blue Jet Healthcare Limited | 531.85 Million INR | -867.829% |
| Concord Biotech Limited | 1.45 Billion INR | -252.633% |
| Jubilant Ingrevia Limited | 6.67 Billion INR | 22.828% |
| Lyka Labs Limited | 599.4 Million INR | -758.749% |
| Panacea Biotec Limited | 1.99 Billion INR | -157.963% |
| Piramal Pharma Limited | 19.91 Billion INR | 74.152% |
| SMS Lifesciences India Limited | 602.96 Million INR | -753.679% |
| Supriya Lifescience Limited | 1.08 Billion INR | -376.545% |
| Syngene International Limited | 5.99 Billion INR | 14.138% |
| TAKE Solutions Limited | 396.91 Million INR | -1196.868% |
| Zota Health Care Limited | 457.83 Million INR | -1024.292% |